Aeon Biopharma Inc (AEON)

$0.94 +0.03 (3.43%)
Market Cap 10.58M
Revenue (ttm) 0.00
Net Income (ttm) 42.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 182,000
Avg Vol 214,454
Day's Range N/A - N/A
Shares Out 11.64M
Stochastic %K 12%
Beta 0.74
Analysts Strong Sell
Price Target $7.20

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 354 6499
Address:
5 Park Plaza, Suite 1750, Irvine, United States
Mandi63
Mandi63 Oct. 24 at 2:05 PM
$AEON
0 · Reply
ka1954
ka1954 Oct. 23 at 4:26 PM
$AEON it's not cooked. volume is 236k only. people just selling like it's going bankrupt. they will buy at higher rates later
1 · Reply
Moonster25
Moonster25 Oct. 23 at 4:22 PM
$AEON This is unbelievable, this might be cooked
0 · Reply
Mandi63
Mandi63 Oct. 23 at 2:58 PM
$AEON
0 · Reply
ka1954
ka1954 Oct. 23 at 2:40 PM
$AEON 10 days below
1 · Reply
Mandi63
Mandi63 Oct. 23 at 2:18 PM
$AEON actually today is the 10th day…
1 · Reply
killer_7
killer_7 Oct. 23 at 2:12 PM
$AEON thank you for the gift
0 · Reply
ka1954
ka1954 Oct. 23 at 2:10 PM
$AEON why the fuck some u buy stock if u cant hold anything. u guys r acting like this will never go 2+
0 · Reply
ka1954
ka1954 Oct. 23 at 2:02 PM
$AEON we have met the compliance, this is the time to buy not sell. keep selling guys, i will wait
1 · Reply
Moonster25
Moonster25 Oct. 22 at 8:30 PM
$AEON Just gross
0 · Reply
Latest News on AEON
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Oct 1, 2025, 8:00 AM EDT - 24 days ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 2 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

May 23, 2025, 4:05 PM EDT - 5 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 19, 2025, 4:05 PM EDT - 5 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 5 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 8 months ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 8 months ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 9 months ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 10 months ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 10 months ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 1 year ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 1 year ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 1 year ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 1 year ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Mandi63
Mandi63 Oct. 24 at 2:05 PM
$AEON
0 · Reply
ka1954
ka1954 Oct. 23 at 4:26 PM
$AEON it's not cooked. volume is 236k only. people just selling like it's going bankrupt. they will buy at higher rates later
1 · Reply
Moonster25
Moonster25 Oct. 23 at 4:22 PM
$AEON This is unbelievable, this might be cooked
0 · Reply
Mandi63
Mandi63 Oct. 23 at 2:58 PM
$AEON
0 · Reply
ka1954
ka1954 Oct. 23 at 2:40 PM
$AEON 10 days below
1 · Reply
Mandi63
Mandi63 Oct. 23 at 2:18 PM
$AEON actually today is the 10th day…
1 · Reply
killer_7
killer_7 Oct. 23 at 2:12 PM
$AEON thank you for the gift
0 · Reply
ka1954
ka1954 Oct. 23 at 2:10 PM
$AEON why the fuck some u buy stock if u cant hold anything. u guys r acting like this will never go 2+
0 · Reply
ka1954
ka1954 Oct. 23 at 2:02 PM
$AEON we have met the compliance, this is the time to buy not sell. keep selling guys, i will wait
1 · Reply
Moonster25
Moonster25 Oct. 22 at 8:30 PM
$AEON Just gross
0 · Reply
ka1954
ka1954 Oct. 22 at 7:55 PM
$AEON too many games being played. just go already to 2+
0 · Reply
ka1954
ka1954 Oct. 22 at 4:10 PM
$AEON today is the last day of nasdaq compliance. can i close above $1?
1 · Reply
Mandi63
Mandi63 Oct. 22 at 3:47 PM
$AEON RAISE YOUR ASK…JUST BUY…WE GOT GREAT NEWS COMING.
0 · Reply
killer_7
killer_7 Oct. 22 at 1:28 PM
$AEON
0 · Reply
Mandi63
Mandi63 Oct. 22 at 1:03 PM
$AEON We are going to have our day…countdown….BROAD FDA APPROVAL COMING…COUTDOWN
0 · Reply
killer_7
killer_7 Oct. 22 at 7:25 AM
$AEON 1.55 today 👌
0 · Reply
killer_7
killer_7 Oct. 20 at 9:35 PM
$AEON let’s goo to the moon
0 · Reply
Mandi63
Mandi63 Oct. 20 at 5:48 PM
$AEON $EOLS $SANA $FEMY $OSCR
0 · Reply
killer_7
killer_7 Oct. 20 at 3:21 PM
$AEON
0 · Reply
Gravy_Trains
Gravy_Trains Oct. 18 at 1:15 AM
$BCG 🚀Well I’ve been telling you to buy. We are heading to $4+ next week. $SUGP Nice pop! $AREB Tough one, I stayed away for now $AEON Looking at it for entry $CERO Almost to buy zone
0 · Reply
Amb8675309
Amb8675309 Oct. 17 at 7:53 PM
$AEON why down sooooo much?🤔
1 · Reply
ka1954
ka1954 Oct. 17 at 7:05 PM
$AEON hold ur position. they r playing games.
1 · Reply